Merck & Co. Forecast, price target & analysts
Merck & Co. Target price 2026 - Analyst rating & recommendation
Merck & Co. Classifications & Recommendation
Merck & Co. Price Target
| Target Price | $155.55 |
| Price | $145.19 |
| Potential | 7.14% |
| Number of Estimates | 31 |
| 31 Analysts have issued a price target Merck & Co. 2027 . The average Merck & Co. target price is $155.55. This is 7.14% higher than the current stock price. The highest price target is $195.30 34.51% , the lowest is $106.05 26.96% . | |
| A rating was issued by 36 analysts: 26 Analysts recommend Merck & Co. to buy, 10 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Merck & Co. stock has an average upside potential 2027 of 7.14% . Most analysts recommend the Merck & Co. stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
31 Analysts have issued a sales forecast Merck & Co. 2026 . The average Merck & Co. sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
16 Analysts have issued an Merck & Co. EBITDA forecast 2026. The average Merck & Co. EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
31 Merck & Co. Analysts have issued a net profit forecast 2026. The average Merck & Co. net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
Current Merck & Co. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Oct 12 2026 |
| Citigroup |
Neutral
➜
Neutral
|
Unchanged | Oct 12 2026 |
| Cantor Fitzgerald |
Neutral
➜
Neutral
|
Unchanged | Oct 08 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Oct 07 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Oct 05 2026 |
| Scotiabank |
Sector Outperform
➜
Sector Outperform
|
Unchanged | Sep 29 2026 |
| HSBC |
Buy
➜
Buy
|
Unchanged | Sep 10 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Oct 12 2026 |
|
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Oct 12 2026 |
|
Unchanged
Cantor Fitzgerald:
Neutral
➜
Neutral
|
Oct 08 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Oct 07 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Oct 05 2026 |
|
Unchanged
Scotiabank:
Sector Outperform
➜
Sector Outperform
|
Sep 29 2026 |
|
Unchanged
HSBC:
Buy
➜
Buy
|
Sep 10 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
